問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Veterans General Hosptial

  • 0

    Total Beds

  • 0

    Total Doctors

  • 807Kaohsiung CityKaohsiung Sanmin

Recruiting Trial

129Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

377Cases

2010-02-10 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2008-12-15 - 2012-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-11-01 - 2016-06-20

Phase III

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

  • Condition/Disease

    Acute Bacterial Skin and SkinStructure Infections

  • Test Drug

    Tedizolid Phosphate

Participate Sites
7Sites

Study ended7Sites

2009-07-01 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

  • Condition/Disease

    neutropenic

  • Test Drug

    amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2016-09-30 - 2019-12-31

Phase II

A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

  • Condition/Disease

    Active psoriatic arthritis

  • Test Drug

    BI655066

Participate Sites
9Sites

Terminated7Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

黃春明
China Medical University Hospital-Taipei

未分科

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-07-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-09-01 - 2012-07-01

Phase III

A phase III randomized, double-blind, placebo-controlled, parallel trial to evaluate BI 10773 (10 mg, 25 mg) orally once a day for a 24 week course of treatment after treatment with Metformin or combined Metformin and Sulfonylurea Efficacy and safety of type 2 diabetes patients with poor blood glucose control

  • Condition/Disease

    Type 2 or unspecified diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

1 34 35 36 37 38
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB